Allena Pharmaceuticals, Inc. (ALNA): Price and Financial Metrics


Allena Pharmaceuticals, Inc. (ALNA): $0.92

0.01 (+0.60%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ALNA Stock Price Chart Interactive Chart >

Price chart for ALNA

ALNA Price/Volume Stats

Current price $0.92 52-week high $2.78
Prev. close $0.92 52-week low $0.75
Day low $0.92 Volume 489,700
Day high $0.94 Avg. volume 1,952,579
50-day MA $0.94 Dividend yield N/A
200-day MA $1.29 Market Cap 73.88M

Allena Pharmaceuticals, Inc. (ALNA) Company Bio


Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company’s lead product candidate includes ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It is also involved in developing ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is based in Newton, Massachusetts.


ALNA Latest News Stream


Event/Time News Detail
Loading, please wait...

ALNA Latest Social Stream


Loading social stream, please wait...

View Full ALNA Social Stream

Latest ALNA News From Around the Web

Below are the latest news stories about Allena Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALNA as an investment opportunity.

Allena Pharmaceuticals to Participate in H.C. Wainwright’s 23rd Annual Global Investment Conference

NEWTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today announced that company management will virtually participate in H.C. Wainwright’s 23rd Annual Global Investment Conference, being held September 13th – 15th, 2021. Louis Brenner, M.D., Allena’s

Yahoo | September 9, 2021

Allena Pharmaceuticals: a Penny Stock with Potential

Allena Pharmaceuticals (ALNA), a late-stage biopharmaceutical company, announced its Q2 results on Tuesday. The company develops oral enzyme therapeutics for the treatment of metabolic diseases and kidney disorders. The company did not earn any revenues in Q2, and its net loss almost doubled from the same quarter of last year to $14 million. The increase in net loss was driven by the rise in Allena’s operating expenses, including research and development, and general and administrative expenses. Last month, the company completed a $28-million direct public offering, resulting in net proceeds of $25.4 million. At the end of Q2, ALNA had a cash and cash equivalents balance of $26.7 million.

Shrilekha Pethe on TipRanks | August 13, 2021

Allena Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Corporate Progress

NEWTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (Allena or the Company), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today reported financial results for the second quarter ended June 30, 2021 and highlighted recent corporate progress.

Intrado Digital Media | August 10, 2021

Allena Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference

NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in the upcoming 12 th Annual Wedbush PacGrow Healthcare Conference on August 10 th August 11 th , 2021.

Intrado Digital Media | August 3, 2021

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the granting of inducement awards to two new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were made as a material inducement to each employee’s entry into e

Yahoo | August 3, 2021

Read More 'ALNA' Stories Here

ALNA Price Returns

1-mo -5.17%
3-mo -29.23%
6-mo -33.33%
1-year -24.59%
3-year -91.43%
5-year N/A
YTD -28.13%
2020 -53.11%
2019 -49.91%
2018 -45.83%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7783 seconds.